SIGA - SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise

• SIGA Technologies ( NASDAQ: SIGA ) announced Tuesday that the company will deliver approximately $26M worth of treatment courses of its lead product TPOXX in 2023 after the U.S. government decided to exercise a procurement option.
• TPOXX, indicated in the U.S. for smallpox, is currently used to treat monkeypox under the FDA’s Animal Rule.
• The exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services (HHS) by the Biomedical Advanced Research and Development Authority (BARDA) requires SIGA ( SIGA ) to deliver the IV formulation of TPOXX.
• “The exercised options are among many procurement options under the 19C contract that remain to be exercised,” Chief Executive Phil Gomez remarked.
• The unexercised options under the 19C BARDA Contract amount to potential payments up to approximately $311.1M in total, SIGA ( SIGA ) disclosed in its latest 10-Q filing.

For further details see: